1
|
Mouly L, Gilhodes J, Lemarié A, Cohen-Jonathan Moyal E, Toulas C, Favre G, Sordet O, Monferran S. The RND1 Small GTPase: Main Functions and Emerging Role in Oncogenesis. Int J Mol Sci 2019; 20:ijms20153612. [PMID: 31344837 PMCID: PMC6696182 DOI: 10.3390/ijms20153612] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2019] [Revised: 07/10/2019] [Accepted: 07/21/2019] [Indexed: 02/07/2023] Open
Abstract
The Rho GTPase family can be classified into classic and atypical members. Classic members cycle between an inactive Guanosine DiPhosphate -bound state and an active Guanosine TriPhosphate-bound state. Atypical Rho GTPases, such as RND1, are predominantly in an active GTP-bound conformation. The role of classic members in oncogenesis has been the subject of numerous studies, while that of atypical members has been less explored. Besides the roles of RND1 in healthy tissues, recent data suggest that RND1 is involved in oncogenesis and response to cancer therapeutics. Here, we present the current knowledge on RND1 expression, subcellular localization, and functions in healthy tissues. Then, we review data showing that RND1 expression is dysregulated in tumors, the molecular mechanisms involved in this deregulation, and the role of RND1 in oncogenesis. For several aggressive tumors, RND1 presents the features of a tumor suppressor gene. In these tumors, low expression of RND1 is associated with a bad prognosis for the patients. Finally, we highlight that RND1 expression is induced by anticancer agents and modulates their response. Of note, RND1 mRNA levels in tumors could be used as a predictive marker of both patient prognosis and response to anticancer agents.
Collapse
Affiliation(s)
- Laetitia Mouly
- Cancer Research Center of Toulouse, INSERM UMR1037, 31037 Toulouse, France
- Faculty of Pharmacy and Medecine, Université Toulouse III, 31062 Toulouse, France
| | - Julia Gilhodes
- Institut Claudius Regaud, IUCT-O, 31059 Toulouse, France
| | - Anthony Lemarié
- Cancer Research Center of Toulouse, INSERM UMR1037, 31037 Toulouse, France
- Faculty of Pharmacy and Medecine, Université Toulouse III, 31062 Toulouse, France
| | - Elizabeth Cohen-Jonathan Moyal
- Cancer Research Center of Toulouse, INSERM UMR1037, 31037 Toulouse, France
- Faculty of Pharmacy and Medecine, Université Toulouse III, 31062 Toulouse, France
- Institut Claudius Regaud, IUCT-O, 31059 Toulouse, France
| | - Christine Toulas
- Cancer Research Center of Toulouse, INSERM UMR1037, 31037 Toulouse, France
- Institut Claudius Regaud, IUCT-O, 31059 Toulouse, France
| | - Gilles Favre
- Cancer Research Center of Toulouse, INSERM UMR1037, 31037 Toulouse, France
- Faculty of Pharmacy and Medecine, Université Toulouse III, 31062 Toulouse, France
- Institut Claudius Regaud, IUCT-O, 31059 Toulouse, France
| | - Olivier Sordet
- Cancer Research Center of Toulouse, INSERM UMR1037, 31037 Toulouse, France
| | - Sylvie Monferran
- Cancer Research Center of Toulouse, INSERM UMR1037, 31037 Toulouse, France.
- Faculty of Pharmacy and Medecine, Université Toulouse III, 31062 Toulouse, France.
| |
Collapse
|
2
|
Mouly L, Mamouni K, Gence R, Cristini A, Cherier J, Castinel A, Legrand M, Favre G, Sordet O, Monferran S. PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin. Cell Death Dis 2018; 9:931. [PMID: 30209297 PMCID: PMC6135836 DOI: 10.1038/s41419-018-0981-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2018] [Revised: 08/02/2018] [Accepted: 08/20/2018] [Indexed: 02/02/2023]
Abstract
RHO GTPases regulate essential functions such as the organization of the actin cytoskeleton. The classic members cycle between an active GTP-bound and an inactive GDP-bound conformation whereas atypical members are predominantly GTP-bound. Besides their well-established role, the classic RHO GTPases RHOB and RAC1, are rapidly induced and/or activated by genotoxic stress and contribute to the DNA damage response. Here we used camptothecin, a selective topoisomerase I (TOP1) inhibitor that stabilizes TOP1 cleavage complexes (TOP1cc), to search for other potential early DNA damage-inducible RHO GTPase genes. We identified that an atypical RHO GTPase, RND1, is rapidly induced by camptothecin. RND1 induction is closely associated with the presence of TOP1cc induced by camptothecin or by DNA lesions that elevate TOP1cc levels such as UV and hydrogen peroxide. We further demonstrated that camptothecin increases RND1 gene transcription and mRNA stability. Camptothecin also increases poly(ADP-ribose) polymerase 1 (PARP-1) activity, whose inhibition reduces RND1 transcription. In addition, overexpression of RND1 increases PARP-1, suggesting a cross-talk between PARP-1 and RND1. Finally, RND1 protects cells against camptothecin-induced apoptosis, and hence favors cellular resistance to camptothecin. Together, these findings highlight RND1 as an atypical RHO GTPase early induced by TOP1cc, and show that the TOP1cc-PARP-1-RND1 pathway protects cells against apoptosis induced by camptothecin.
Collapse
Affiliation(s)
- Laetitia Mouly
- Cancer Research Center of Toulouse (CRCT), INSERM, Université de Toulouse, Université Toulouse III Paul Sabatier, CNRS, Toulouse, France.,Faculté des Sciences Pharmaceutiques, Université de Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Kenza Mamouni
- Cancer Research Center of Toulouse (CRCT), INSERM, Université de Toulouse, Université Toulouse III Paul Sabatier, CNRS, Toulouse, France.,Faculté des Sciences Pharmaceutiques, Université de Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Remi Gence
- Cancer Research Center of Toulouse (CRCT), INSERM, Université de Toulouse, Université Toulouse III Paul Sabatier, CNRS, Toulouse, France.,Faculté des Sciences Pharmaceutiques, Université de Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Agnese Cristini
- Cancer Research Center of Toulouse (CRCT), INSERM, Université de Toulouse, Université Toulouse III Paul Sabatier, CNRS, Toulouse, France.,Faculté des Sciences Pharmaceutiques, Université de Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Julia Cherier
- Cancer Research Center of Toulouse (CRCT), INSERM, Université de Toulouse, Université Toulouse III Paul Sabatier, CNRS, Toulouse, France
| | - Adrien Castinel
- Faculté des Sciences Pharmaceutiques, Université de Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Morgane Legrand
- Faculté des Sciences Pharmaceutiques, Université de Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Gilles Favre
- Cancer Research Center of Toulouse (CRCT), INSERM, Université de Toulouse, Université Toulouse III Paul Sabatier, CNRS, Toulouse, France.,Faculté des Sciences Pharmaceutiques, Université de Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Olivier Sordet
- Cancer Research Center of Toulouse (CRCT), INSERM, Université de Toulouse, Université Toulouse III Paul Sabatier, CNRS, Toulouse, France.
| | - Sylvie Monferran
- Cancer Research Center of Toulouse (CRCT), INSERM, Université de Toulouse, Université Toulouse III Paul Sabatier, CNRS, Toulouse, France. .,Faculté des Sciences Pharmaceutiques, Université de Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France.
| |
Collapse
|